Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.
The assessment of severity of TBI patients is based on the Glasgow Coma Scale (GCS) and the initial management in the ED includes performing a non-contrast brain Computed Tomography (CT) scan if the patient meets specific conditions. To date, real world data show that EDs would actually not follow guideline recommendations and a substantial CT overuse is observed. Management strategies are becoming more and more focused on selective CT use to effectively manage health care resources. Efforts have been made to optimize the indications for brain CT scan after mTBI. Although brain CT scan plays a central role after mTBI, there is an unmet clinical need for an objective tool to optimize indications for CT scan, reduce patient radiation exposure, and possibly predict patient outcome. Clinical Decision Rules for an initial CT-scan could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjects with Mild Traumatic Brain injury | Experimental | Subjects presenting to the ED within 12 hours of suspected mild head trauma and a Glasgow Score of 13-15 undergo to blood collection for VIDAS® TBI [GFAP, UCH-L1] testing. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VIDAS® TBI Test [GFAP and UCH-L1 assays] | Diagnostic Test | The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation. |
| Measure | Description | Time Frame |
|---|---|---|
| To determine VIDAS® TBI sensitivity to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma | |
| To determine VIDAS® TBI specificity to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma | |
| To determine VIDAS® TBI Positive Predictive Value to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma | |
| To determine VIDAS® TBI Negative Predictive Value to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma | |
| To determine VIDAS® TBI Positive Likelihood Ratio to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma | |
| To assess VIDAS® TBI Negative Likelihood Ratio to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma |
| Measure | Description | Time Frame |
|---|---|---|
| To determine Canadian CT Head Rule specificity combined to VIDAS specificity to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma | |
| To determine Canadian CT Head Rule sensitivity combined to VIDAS sensitivity to exclude the presence of an intracranial lesion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Orlando Health | Orlando | Florida | 32806 | United States | ||
| Wayne State University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001924 | Brain Concussion |
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D000070642 | Brain Injuries, Traumatic |
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Single Prospective Cohort. Multicentric, International clinical study.
Not provided
Not provided
Not provided
Not provided
|
| 12 hours post mild brain trauma |
| To determine Canadian CT Head Rule Positive Predictive Value combined to VIDAS positive Predictive Value to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma |
| To determine Canadian CT Head Rule Negative Predictive Value combined to VIDAS Negative Predictive Value to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma |
| To determine Canadian CT Head Rule Negative Likelihood Ratio combined to VIDAS Negative Likelihood Ration to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma |
| To determine Canadian CT Head Rule Positive Likelihood Ratio combined to VIDAS Positive Likelihood Ration to exclude the presence of an intracranial lesion | 12 hours post mild brain trauma |
| To estimate the impact of the use of VIDAS® TBI on the time to discharge | 3 months |
| To estimate the expected impact of the use of VIDAS® TBI on patient stay in the ED | 3 months |
| To estimate the expected impact of the use of VIDAS® TBI on hospitalization decision | 3 months |
| To estimate the expected impact of the use of VIDAS® TBI on time to medical decision | 3 months |
| To estimate the impact of the use of VIDAS® TBI on the patient's monitoring duration | 3 months |
| to measure the percentage of CT-scan potentially avoided | 3 months |
| To estimate the saving costs when using VIDAS® TBI in comparison with usual clinical sites' care. | 3 months |
| To estimate the costs of Length of stay in Emergency Department (ED) when using VIDAS® TBI in comparison with usual clinical sites' care. | 3 months |
| To estimate the associated costs of Length of stay in the hospital when using VIDAS® TBI in comparison with usual clinical sites' care. | 3 months |
| Detroit |
| Michigan |
| 48202 |
| United States |
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| Washington University | St Louis | Missouri | 63130 | United States |
| University of Rochester | Rochester | New York | 14627 | United States |
| D009422 | Nervous System Diseases |
| D006259 | Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D016489 | Head Injuries, Closed |
| D014947 | Wounds and Injuries |
| D014949 | Wounds, Nonpenetrating |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |